RecruitingNCT06212947
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
Sponsor
BioMarin Pharmaceutical
Enrollment
400 participants
Start Date
Nov 27, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.
Eligibility
Max Age: 15 Years
Inclusion Criteria2
- Participants must be ≤ 15 years old at the time of signing the informed consent
- Participants must have genetic confirmation of Hypochondroplasia diagnosis
Exclusion Criteria2
- Have a diagnosis of another genetic short stature condition other than Hypochondroplasia or a genetic variant known to cause another genetic syndrome associated with short stature
- Received an investigational product or medical device within 6 months before the Screening visit
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(43)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06212947
Related Trials
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT0712626226 locations
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
NCT073889661 location
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT0641097625 locations
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
NCT053280501 location